Status:
COMPLETED
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
Lead Sponsor:
Novartis
Conditions:
Primary Insulin Hypersecretion
Obesity
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study is in patients with at least moderate obesity (Body Mass Index \[BMI\] \> 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar...
Eligibility Criteria
Inclusion
- You may qualify for this study if you:
- are between the ages of 18-70 (male or female)
- are at least moderately obese (BMI \> 30 kg/m2 or approximately 30 or more pounds overweight)
- and pass an oral glucose tolerance test (a 3 hour test to determine if your body produces too much insulin)
Exclusion
- You are not qualified for this study if you:
- have diabetes
- have been able to lose weight with diet and exercise alone
- have previously received Sandostatin LAR® Depot
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2002
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00094146
Start Date
January 1 2002
End Date
December 1 2002
Last Update
September 22 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
New Orleans Center for Clinical Research
New Orleans, Louisiana, United States
2
University of Tennessee
Memphis, Tennessee, United States, 38103
3
University of Wisconsin Beers-Murphy Clinical Nutrition Clinic
Madison, Wisconsin, United States, 537052